Atlas Trials

Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer

Clinical trial NCT01340430 · COMPLETED

Trial details

NCT number
NCT01340430
Sponsor
Lucia Del Mastro,MD
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
HER-2 Positive Breast Cancer
Start date
2011-03-01
Primary completion
2015-12-01
Enrollment
43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.